Jesse Silveira's questions to Anavex Life Sciences Corp (AVXL) leadership • Q3 2025
Question
Jesse Silveira of Spirit of the Coast Analytics asked about the theoretical use of CRISPR technology to enhance blarcamesine's efficacy, the company's plans for an Alzheimer's prevention trial, and the strategic objectives behind retaining a lobbying firm and engaging with policymakers. He also inquired about Anavex's interest in the FDA's new accelerated approval voucher program.
Answer
President & CEO Dr. Christopher Missling acknowledged that CRISPR is theoretically possible but stated it's largely unnecessary as most patients have a functional sigma-1 gene. He confirmed Anavex plans a preventative trial based on positive preclinical data but noted it is resource-dependent and will follow the initial drug launch. Regarding lobbying, Dr. Missling described it as a standard industry practice to raise awareness and educate policymakers on the unmet needs in Alzheimer's disease. He affirmed the company's strong interest in the FDA's accelerated voucher program, viewing it as independent of any EMA decisions.